DOD Peer Reviewed Cancer Translational New Investigator Award

Post Date

May 20th 2010

Application Due Date

October 20th 2010

Funding Opportunity Number

W81XWH-10-PRCRP-TNIA

CFDA Number(s)

12.420

Funding Instrument Type(s)

Cooperative Agreement
Grant

Funding Activity Categories

Science and Technology and other Research and Development

Number of Awards

10

Eligibility Categories

Unrestricted

Funding

• Estimated Total Funding:

  $4500000

• Award Range:

  $None - $None

Grant Description

The PRCRP Translational New Investigator Award mechanism is being offered for the first time in FY10. The Translational New Investigator Award supports the development of translational research partnerships among two independent investigators to address at least one of the FY10 PRCRP Topic Areas in a manner relevant to military beneficiaries. Within the partnership, one member must be a laboratory scientist and the other must be a clinician. This award is intended to support a mentoring partnership between a new investigator (the Principal Investigator [PI]) and a mentor (a clinician or laboratory scientist with an established research program in one of the FY10 PRCRP Topic Areas). The ultimate goal of translational research is to move an observation forward into a clinical application. Research does not have to be performed in the clinic but should include human anatomical substances. The Translational New Investigator Award supports preclinical studies in animal models and/or human anatomical substances that have clear potential for translation into clinical applications. Correlative studies that are associated with an existing clinical trial, and/or projects that develop clinical endpoints for clinical trials may be proposed. Developing the research plan must involve a reciprocal flow of ideas and information within the research team (from bench to bedside, and from bedside to bench). Research involving human subject participation is permitted under this funding opportunity but is restricted to studies without clinical trials. Clinical trials are not permitted under this award mechanism. In general, a clinical trial is defined as a prospective study where an intervention (e.g., a device, drug, behavioral, surgical procedure) is tested on human subjects for a measurable outcome. Correlative Human Subject Use (clinical research) studies are permitted, and the study may be associated with a clinical trial, but it does not seek the main outcomes of the clinical trial. Correlative studies are defined as a prospective or retrospective collection of human anatomical substances (tissue, blood, nail clippings, bone marrow, behavioral documentation, etc.) to be used in research to answer a question regarding the disease and /or interventions. Correlative studies do not include the direct testing for the outcome of any intervention for the prevention, diagnosis, treatment, or evaluation of the quality of life of the patient. Correlative Human Subject Use may require informed consent of the human subject, and may include identifiable information. Refer to the General Application Instructions, Appendix 5, for additional information about studies involving human subjects, human subjects data, or human anatomical substances. For FY10, the PRCRP Translational New Investigator Award will only consider applications that address one or more of the following FY10 PRCRP Topic Areas.

Contact Information

• Agency

  Department of Defense

• Office:

  Dept. of the Army -- USAMRAA

• Agency Contact:

  PA HELP: 301-619-7079; cdmrp.pa@amedd.army.mil
  eReceipt HELP: 301-682-5507; help@cdmrp.org
  

• Agency Mailing Address:

  CDMRP help Desk

• Agency Email Address:

  cdmrp.pa@amedd.army.mil